ResMed Inc. (RMD)
NYSE • Healthcare
November 6, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, ResMed Inc. keeps $30 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Jan 28
in 82 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
ResMed beat expectations on both the top and bottom line in the first fiscal quarter of 2027, based on preliminary results reported October 29, 2026, with EPS of $2.91 topping the $2.69 estimate (+8.2%) and revenue of $1.415 billion topping the $1.394 billion estimate (+1.5%). Revenue rose ~6% to about $1.4 billion (up from $1.336 billion a year ago), supported by its Sleep and Respiratory Care and Software as a Service businesses, while profitability stayed elevated with gross margin at ~62% and operating margin at ~32%. Net income increased 20% year over year to roughly $418 million (up from $348.5 million), alongside the EPS increase from $2.55 a year ago. Cash generation in the quarter included operating cash flow of roughly $422 million, and the company returned capital through about $936 million of share repurchases and roughly $95 million in dividends. For the next period, consensus calls for EPS of $3.03 on revenue of $1.453 billion.
About ResMed Inc.
ResMed Inc. (NYSE: RMD) makes and markets healthcare devices and connected digital solutions for sleep, respiratory, and out-of-hospital care. The company operates in the medical technology field and generated $5.1 billion in revenue in FY2025. Its business spans device hardware, software, and related services used across clinical and home-based care settings.
Today's Snapshot
The day ended with RMD 1.7% lower at 235.31, while its sector was flat. ResMed started fiscal 2027 with $1 billion in revenue and higher earnings.
Trading Volume
Below 10d avg (1.7M)
1.3M
vs S&P 500 Today
Underperforming Market
-2.07%
Updated: November 6, 2026 at 21:08 UTC
RMD Headlines
ResMed launches AirTouch F40 mask in U.S.
October 23, 2026
3 min readRTX, P&G and ResMed in Focus After New Updates
April 20, 2026
6 min readInstitutions Shift Positions in Major Blue-Chip Stocks
April 17, 2026
5 min read2025 Valuation Insights: Spotify, Aker BP, and Key Growth Stocks
December 7, 2025
5 min readTechnical Indicators
All signalsHide signals
- EMA (5 indicators)$227.30 - $238.92Buy
- RSI (14)48.27Neutral
- Stochastic %K (14, 3, 3)49.39Neutral
- MACD Level (12, 26)1.73Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.